Dr. Crinò on Crizotinib in ALK-Positive NSCLC

Video

Lucio Crinò, MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer

Lucio Crinò, MD, Director, Department of Oncology, University Hospital of Perugia, Italy, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer (NSCLC).

In this phase III trial, Crinò says, crizotinib showed superior activity compared with chemotherapy in patients with ALK+ NSCLC. Crizotinib showed a response rate of 65-70% compared to standard therapy, which only showed a response rate of about 10-28%, Crinò says.

There was also a significant improvement in progression-free survival. While standard treatments such as chemotherapy only show a progression-free survival rate of 3.5 months, Crinò says, there is a progression-free survival rate approaching 8 or 9 months with crizotinib.

<<<

View more from the 2013 European Cancer Congress

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.